Formulation And Evaluation Of Benazepril Hydrochloride Transdermal Films For Controlled Drug Release

The current research deals with formulation and evaluation of Benazepril hydrochloride transdermal films, by varying ratios of polymers Eudragit RL100, Eudragit RS100 by film casting technique. Preformulation studies were conducted to check the solubility, melting point and partition coefficient. The eleven formulations were analyzed for physicochemical parameters and drug dissolution potential of transdermal films. All the formulations are transparent with minimum weight variation and uniform thickness. The drug content uniformity of all the formulations vary between 96.84 ± 3.7% to 96.98 ± 1.6% indicate uniform drug distribution. The low water vapour transmission values indicate good water vapour permeation. The folding endurance is between 246 ± 4.60 to 315 ± 4.13 indicates that the transdermal films can withstand rupture. In vitro drug dissolution study indicates maximum amount of drug 96.8% (F2) released in 24 h when compared with marketed formulation 84.81%. The release order follows Fickian diffusion. The formulation F2 was optimized based on drug flux, permeability coefficient and enhancement ratio.

Separation And Analysis Of Amlodipine/Benazepril Combination In Capsules By A Novel Ion Pair Liquid Chromatography

Objective: The objective of this study was to develop and validate a novel ion-pair liquid chromatography method, in order to separate and assay of amlodipine/benazepril combination in capsules. This method was a fast, practical and additional choice in quality control laboratories. Methods: The chromatographic conditions comprised of a classical C18-type stationary phase (250 × 4.6 mm, 5μ), with a mobile phase consisting of: 45% of 10-3 M of cetrimide and 55% acetonitrile. The flow rate was 1 ml/min; the detection wavelength was at 242 nm, under ambient temperature. Results: The method was validated for linearity with correlation coefficients very close to one, the accuracy with mean recovery values between 95.0-105.0%, precision with relative standard deviations of the calculated concentrations less than 5.0% and specificity in the presence of degradation products and excipients. Conclusion: The results presented in this paper showed that the developed method was fast and applicable, for the separation and determination of amlodipine/benazepril combination in capsules.

Influence of bisoprolol combined benazepril on ECG and left ventricular diastolic function in hyperten‐sive patients with acute heart failure／ / 心血管康复医学杂志

To explore influence of bisoprolol combined benazepril on ECG and left ventricular diastolic function in hypertensive patients with acute heart failure (AHF).Methods :A total of 124 hypertensive patients with AHF were randomly and equally divided into routine treatment group and combined treatment group (received biso‐prolol combined benazepril based on routine treatment ) ,both groups were treated for two months .Therapeutic effect ,ECG indexes ,left ventricular diastolic function indexes ,levels of heart failure and myocardial injury markers etc .before and after treatment were compared between two groups .Results : After two‐month treatment ,total ef‐fective rate of combined treatment group was significantly higher than that of routine treatment group (96. 77% vs. 82. 26%, P＝0.008) ;compared with routine treatment group ,there were significant reductions in QRS wave dura‐tion [ (103. 87 ± 9.70) ms vs.(94.12 ± 8. 93) ms] ,QTc duration [ (432.37 ± 33. 24) msvs .(418.96 ± 29. 64) ms] , plane QRS‐T angle [ (59.75 ± 26. 61)°vs.(48.19 ± 22.30)°] ,mitral annulus late diastolic peak flow velocity (Am) [ (12.84 ± 3.40) cm／svs .(11. 39 ± 3. 11) cm／s] ,plasma levels of N terminal pro brain natriuretic peptide [ (1. 20 ± 0.58) μg／L vs .(0. 75 ± 0.47) μg／L] ,carbohydrate antigen 125 [ (19.10 ± 9.24) U／ml vs.(13.93 ± 7.85) U／ml] ,galectin‐3 [ (4.72 ± 2. 25) μg／L vs .(3.28 ± 1. 65) μg／L] ,cardiac troponin I [ (1.93 ± 0. 97) μg／L vs.(1. 46 ± 0. 85) μg／L] ,and significant rise in mitral early／late diastolic peak flow velocity (E／A) [(1. 18 ± 0.30) vs.(1. 31 ± 0. 28)] and mitral annulus early diastolic peak flow velocity (Em) [ (12.90 ± 3. 76) cm／svs.(14. 49 ± 3.25) cm／s] in combined treatment group , P＜0. 05 or ＜0.01. There was no significant difference in incidence rates of ad‐verse reactions between two groups , P＞0.05 all.Conclusion :Bisoprolol combined benazepril possesses significant therapeutic effect on hypertensive patients with AHF ,and its improving effect on ECG indexes and left ventricular diastolic function is significant .

Effect of benazepril on nuclear factor E2 related factor 2, nicotinamide adenine dinucleotide phosphate oxidase and reactive oxygen species in rats with hepatic fibrosis / 中华肝脏病杂志

Objective@#To study the effect of benazepril on the expression of nuclear factor E2 related factor 2 (Nrf2), nicotinamide adenine dinucleotide phosphate oxidase 4 (NOX4) and reactive oxygen species (ROS) concentration in rats with hepatic fibrosis and to explore the possible antifibrotic mechanism of benazepril.@*Methods@#Twenty-two healthy male Sprague-Dawley rats were randomly divided into 3 groups: control group (6 rats), model group (8 rats) and benazepril treatment group (8 rats). Two rats died during modeling and treatment in the model group and the benazepril treatment group, and a model of hepatic fibrosis induced by carbon tetrachloride (CCL4) was established. The rats in benazepril group were given benazepril for 8 weeks by gastric gavage. The assessment of liver tissue damage in each group was measured using conventional hematoxylin-eosin and Masson staining. The mRNA level of Nrf2, NOX4 in liver tissue was detected by RT-PCR, and serum ROS concentration was determined by colorimetry. All data were expressed in mean ± standard deviations, and were analyzed using SPSS21.0 statistical software. The data were compared using one-way analysis of variance, and the LSD-t method was used for pairwise comparison between the two groups. The correlation analysis was performed by Spearman’s correlation analysis.@*Results@#In the liver of the model group, with the aggravation of liver fibrosis the expression of Nrf2mRNA, NOX4 mRNA and ROS concentration were higher than control group [(4.01 ± 3.40), (31.78 ± 3.96), (1.82 ± 0.46) μg/ ml vs. (0.12 ± 0.11), (2.03 ± 0.31), (1.56±0.84) μg/ml, P < 0.05]. After benazepril treatment, NOX4 mRNA expression and ROS concentration were decreased than the model group [(15.93 ± 5.01), (0.78 ± 0.44) μg/ml vs. (31.78 ± 3.96), (1.82 ± 0.46) μg /ml, P < 0.05], while Nrf2 mRNA expression was higher than the model group [(6.69 ± 4.86) vs. (4.01 ± 3.40), P < 0.05]. There was a positive correlation between Nrf2 and NOX4, Nrf2 and ROS, and NOX4 and ROS (r = 0.616, 0.411, 0.802, P < 0.05).@*Conclusion@#Benazepril may exert an anti-hepatic fibrosis effect by activating Nrf2 expression, or may inhibit the ROS-mediated oxidative stress in response to NOX4.

Influence of rifampin in effectiveness of antihypertensive drugs in patients with hypertension: A case report and literature review / 吉林大学学报(医学版)

Objective: To discuss the diagnosis and treatment process of abnormally elevated blood pressure in the patient treated with rifampicin and antihypertensive drugs, to analyze the interaction between rifampicin and antihypertensive drugs, and to improve the clinicians' understanding of the administration in the patients. Methods: The clinical materials of a patient treated with rifampicin and antihypertensive drugs were collected, and the relationship between the blood pressure change and drug was analyzed. The changes of concentrations of dihydropyridine-based calcium antagonists after administration of rifampin were observed and the relative literatures were reviewed. Results: A 58-year-old man with coughing and coughing for 1 month was admitted to hospital. The patient was definitely diagnosed as tuberculosis and hypertension before admission; the patient was treated with rifampicin, isoniazid, ethambutol, pyrazinamide, and felodipine together. The original treatment plan was continued and the blood pressure of the patient was monitored. On the 9th day of anti-tuberculosis treatment, the patient developed dizziness, chest tightness, and severe fluctuations in blood pressure. Then rifampicin was stopped and antihypertensive drugs were adjusted. At the beginning of blood pressure fluctuation of the patient, the combination of angiotensin-converting enzyme inhibitors and the increasing dose of dihydropyridine-based calcium antagonists did not control the blood pressure. The blood pressure began to decrease significantly at 36 h after rifampin was stopped. On the 18th day of anti-tuberculosis treatment, the original antihypertensive plan was restored and the blood pressure remained stable. Conclusion: Rifampicin can sometimes significantly reduce the effect iveness of antihypertensive drugs (such as dihydropyridine calcium antagonists), and the clinicians should pay attention to it.

The influence of benazepril and amlodipine on the expression of secretin and somatostatin in spontaneously hypertensive rats / 中国应用生理学杂志

OBJECTIVES@#Investigate the influence of benazepril and amlodipine on the expression of secretin (PZ) and somatostatin (SS) in spontaneously hypertensive rats (SHR).@*METHODS@#Forty-five SHRs (14 weeks old, male) were randomly assigned into 3 groups (=15):SHR group, Benazepril group (which was given benazepril 0.90 mg·kg·d) and Amlodipine group (SHRs were given amlodipine 0.45 mg· kg·d), taking WistarKyoto(WKY) as normal control (=15), meanwhile, rats in SHR group and WKY group were given the same volume of distilled water. After 8 weeks of intervention, the expression of protein and mRNA of PZ in duodenum and SS in sinuses ventriculi was detected by enzyme-linked immunoassay and RT-PCR.@*RESULTS@#After 8 weeks of intervention, compared with the WKY group, the expression of protein and mRNA of PZ in duodenum and SS in sinuses ventriculi was increased significantly in SHR group (<0. 05). Compared with SHR group, the expression of PZ in duodenum and SS in sinuses ventriculi was decreased significantly in Benazepril group and Amlodipine group (<0.05). Compared with Benazepril group, in Amlodipine group the expression of PZ mRNA in duodenum and SS mRNA in sinuses ventriculi was decreased more significantly (<0.05).@*CONCLUSIONS@#The regulation disorder of PZ in duodenum and SS in sinuses ventriculi exists in SHR. The antihypertensive effect of benazepril and amlodipine may be realized by regulating the expression of PZ and SS, while the regulation of amlodipine is more obvious than benazepril.

Evaluation of a fixed-dose combination of benazepril and pimobendan in dogs with congestive heart failure: a randomized non-inferiority clinical trial

A fixed-dose combination tablet of benazepril and pimobendan (Fortekor Plus; Elanco Animal Health) was tested in dogs with congestive heart failure (CHF) caused by myxomatous mitral valve disease (MMVD) in a three-arm, masked, randomized, non-inferiority clinical trial in Japan. The test group (n = 34) received Fortekor Plus twice daily. Two control groups received registered formulations of benazepril (Fortekor; Elanco Animal Health) and pimobendan (Vetmedin; Boehringer Ingelheim Vetmedica) with administration of Vetmedin twice daily and Fortekor twice (Control I, n = 14) or once (Control II, n = 19) daily. Diuretics were used in 22 dogs (32.8%). Global clinical scores decreased significantly from baseline in all groups; there were no significant differences between groups, and non-inferiority of Fortekor Plus compared to Control I, Control II, and combined Control I + II groups was demonstrated. There were no significant differences between groups for relevant clinical chemistry and hematology variables or frequency of all adverse events. Frequency of emesis was significantly (p = 0.0042) lower in the Fortekor Plus (8.8%) group than in the Control I + II (39.4%) group. In conclusion, Fortekor Plus had non-inferior efficacy and was associated with significantly less emesis compared to Fortekor and Vetmedin in dogs with CHF caused by MMVD.

Clinical study of benazepril combined with amlodipine in the treatment of essential hypertension / 中国基层医药

Objective To investigate the clinical efficacy of benazepril combined with amlodipine in the treatment of essential hypertension.Methods From January 2016 to January 2017,90 patients with coronary heart disease in Taizhou Central Hospital were selected in the study,and they were randomly divided into three groups,with 30 cases in each group.The observation group(A group)was treated with benazepril combined with amlodipine,the control group (B group )was treated with benazepril,and the control group (C group)was treated with amlodipine. The clinical efficacy,blood pressure,blood lipid changes,blood glucose changes before and after treatment in the three groups were compared.Results The total effective rate of A group was 96.367%,which of B group was 66.67%, which of C group was 70.00%,and the clinical efficacy among the three groups had statistically significant difference (χ2＝11.96,P＜0.05).Before treatment,the systolic blood pressure(SBP)and diastolic blood pressure(DBP)of the three groups had no statistically significant differences(F＝0.98,0.85,all P＞0.05).After treatment,the SBP, DBP of the three groups were significantly lower than those before treatment(t＝5.68,7.21,3.52,3.16,3.64,3.16, all P＜0.05),the SBP and DBP of A group were significantly lower than those of B group and C group(F＝6.24, 3.27,all P＜0.05).After treatment,only the TC,TG,HDL－C levels of A group had statistically significant differ-ences compared with those before treatment(t＝5.29,6.28,2.31,all P＜0.05),and the TC,TG levels of A group were significantly lower than those of B group and C group(F＝3.18,2.86,all P＜0.05),while the HDL－C level of A group increased significantly compared with that of B group and C group(F＝3.78,P＜0.05 ).Before treatment, the FPG,FINS among the three groups had no statistically significant differences (F＝0.85,0.95,all P＞0.05 ). After treatment,only the FPG,FINS of A group had statistically significant differences compared with those before treatment(t＝5.14,3.65,all P＜0.05),and the FPG,FINS of A group were significantly lower than those of B group and C group(F＝5.27,2.86,all P＜0.05).The adverse reaction rate in A group was 6.67%,which in B group was 30.00%,which in group C was 26.67%,and there was no statistically significant difference among the three groups (χ2＝1.72,P＞0.05).Conclusion Benazepril combined with amlodipine in the treatment of essential hypertension is effective,safe,and has less adverse reactions.

Effect of atorvastatin combined with benazepril on proteinuria of patients with IgA nephropathy / 中国基层医药

Objective To investigate the efficacy and safety of atorvastatin combined with benazepril in the treatment of proteinuria in patients with IgA nephropathy ,so as to provide guidance for clinical medication .Methods Eighty patients with IgA nephropathy were selected ,and they were randomly divided into the observation group and control group according to random number table , with 40 patients in each group .The observation group was treated with atorvastatin combined with benazepril ,and the control group was treated with benazepril .The treatment effect of the two groups was compared.Results Before treatment,the 24h urinary protein,mean arterial pressure,serum creat-inine,blood urea nitrogen,and blood potassium between the two groups had no statistically significant differences (t=0.125,1.273,0.321,0.207,0.719,all P>0.05).After treatment,the 24h urine protein and mean arterial blood pressure in the two groups were lower than those before treatment , and the differences were statistically significant (t=2.735,6.145,3.434,4.501,all P<0.05),which in the observation group were lower than those in the control group,the differences were statistically significant (t=3.121,2.170,all P<0.05).The changes of serum creatinine, blood urea nitrogen and serum potassium in the two groups had no statistically significant differences (all P>0.05) .Conclusion Atorvastatin combined with benazepril in the treatment of IgA nephropathy can significantly decrease urinary protein level,without the adverse reactions of increased urea nitrogen ,creatinine and hyperkalemia ,which is worthy of popularization and application .

Safety of benapril combined amlodipine on hypertension and its influence on plasm TC and TG levels / 心血管康复医学杂志

Objective:To explore safety of benapril combined amlodipine on hypertension and its influence on levels of plasm total cholesterol (TC) and triglyceride (TG).Methods:A total of 180 hypertensive patients treated in our hospital were selected,randomly and equally divided into amlodipine group and combined treatment group (received amlodipine combined benapril therapy ),both groups were continuously treated for one month.Therapeutic outcome and incidence of adverse reactions were compared between two groups.Results:After treatment,compared with amlo-dipine group,there were significant reductions in systolic blood pressure [(146.3 ± 11.9) mmHg vs.(133.4 ± 15.1) mm-Hg],diastolic blood pressure [(90.5 ± 5.9) mmHg vs.(81.4 ± 6.1) mmHg],heart rate [(85.4 ± 10.8) beats/min vs.(74.5 ± 12.6) beats/min],levels of plasm TC [(5.17 ± 1.75) mmol vs.(3.52 ± 1.85) mmol] and TG[(1.64 ± 0.14) mmol vs.(1.32 ± 0.32) mmol] in combined treatment group,P＝0.001 all.Total incidence rate of adverse reactions of combined treatment group was significantly lower than that of amlodipine group (3.3% vs.15.6%,P＝0.005).Conclu-sion:Benapril combined amlodipine can significantly reduce heart rate,blood pressure and levels of plasm total cholesterol and triglyceride in hypertensive patients.It＇s safe and effective,which is worth extending.

Improvement Effects of 3 Kinds of Angiotensin Converting Enzyme Inhibitor on Ventricular Remodeling in Patients with Acute Myocardial Infarction / 中国药房

OBJECTIVE: To observe the improvement effects of angiotensin converting enzyme inhibitor (ACEI) fosinopril, perindopril and benazepril on ventricular remodeling in patients with acute myocardial infarction (AMI), and to evaluate its safety. METHODS: A total of 96 AMI patients selected from our hospital during Jan. 2014-Oct. 2016 were divided into group A, B, C according to random number table, with 32 cases in each group. All patients received symptomatic treatment, underwent percutaneous coronary intervention, and then given ACEI after blood vessels recanalization and keeping blood pressure stable. Group A was given Fosinopril sodium tablets 10 mg, qd; group B was given Perindopril tert-butylamine tablets 4 mg, qd; group C was given Benazepril hydrochloride tablets 10 mg, qd. All groups were treated for consecutive 6 months. Cardiac structure and function indexes (LVESD, LVEDD, IVSD, LVPWD, LVEF, CO), hemodynamic indexes (SBP, DBP, HR) and related lab indexes (FPG, TG, TC, HDL-C, LDL-C, AST, ALT, Scr, BUN) of 3 groups were observed before and after treatment. The occurrence of ADR was recorded. RESULTS: Before treatment, there was no statistical significance in cardiac structure and function indexes, hemodynamic indexes or related lab indexes among 3 groups (P＞0. 05). After treatment, the levels of LVESD, LVEDD, LVPWD, CO, HR, FPG, TG, TC and LDL-C in 3 groups were decreased significantly, while the levels of LVEF and SBP were increased significantly, with statistical significance (尸＜0. 05). There was no statistical significance in above indexes among 3 groups after treatment (P＞0. 05). After treatment, the level of Scr in group B was significantly increased and higher than group A and C, with statistical significance (P＜0. 05). There was no statistical significance in the levels of IVSD, DBP, HDL-C, AST, ALT or BUN among 3 groups before and after treatment as well as the level of Scr between group A and C (P＞ 0. 05). There was no statistical significance in the incidence of ADR among 3 groups(P＞0. 05). CONCLUSIONS: Fosinopril, perindopril and benazepril can significantly improve ventricular remodeling in AMI patients, narrowing the heart cavity, increasing systolic pressure, lowering heart rate, reducing the oxygen consumption of the ventricle, with similar effects. Perindopril may increase the level of Scr, so fosinopril and benazepril are safe and suitable for AMI patients with renal function disorder.

Therapeutic effect of vitamin D combined benazepril on reducing urine microalbumin in hypertensive patients / 心血管康复医学杂志

Objective :To study safety and effectiveness of vitamin D combined benazepril on patients with essential hyper-tension (EH) and positive urine microalbumin (UMA).Methods :A total of 92 EH patients with positive UMA were ran-domly divided into benazepril group (n＝44 , received benazepril 5md/d ,placebo 1 capsule/d) and combined treatment group (n＝48 , received vitamin D3 400mg/d and benazepril 5mg/d) ,both groups were treated for 12 weeks.Levels of mean arterial pressure (MAP) ,serum creatinine (SCr) and UMA were measured and compared between two groups before and after treatment .Results :Compared with before treatment ,there were significant reductions in levels of MAP and UMA in two groups after treatment , P＝0.001 all ;compared with benazepril group ,there were significant reductions in levels of MAP [ (108.45 ± 15.09) mmHg vs.(101.1 ± 15.02) mmHg] and UMA [ (52.35 ± 17.45) mg/L vs.(43.75 ± 13.29) mg/L] in combined treatment group ,P＜0.05 or ＜0.01.There was no significant difference in SCr level between two groups before and after treatment , P＞0.05 all.Conclusion : Compared with pure benazepril antihypertensive treat-ment ,vitamin D combined benazepril possesses better therapeutic effect on reducing UMA and antihypertensive effect .And it is safe without obvious damage on kidney function ,which is worth extending .

Selenium and benazepril inhibit renal interstitial fibrosis in rat with unilateral ureteral obstruction / 基础医学与临床

Objective To study the protective effect of the sodium selenite and benazepril on renal interstitial fibro-sis(RIF) in rat model of unilateral ureteral obstruction(UUO) and its mechanism. Methods The male SD of clean grade rats were randomly divided into sham-operation group,UUO group(UUO model was established by li-gating unilateral ureter), UUO+ sodium selenite group group(sodium selenite 0.2 mg/kg·d gavage), UUO+benazepril group(benazepril 10 mg/kg·d gavage),with 18 in each group.At day 7,14 and 21 after thetreatment, 6 rats selected randomly from each group were killed.The extent of RIF was evaluated by HE and Masson staining of the renal tissue. The expression of connective tissue growth factor(CTGF),transforming growth factor-β1(TGF-β1), alpha smooth muscle actin(α-SMA) andⅢ collagen(ColⅢ) were detected by immunohistochemical method.The protein expression of CTGF and TGF-β1 were detected by Western blot. Chemical colorimetric method was used to detecte the contents of supper oxide dismutase (SOD),malondialdehyde (MDA) and glutathione peroxidase (GSH-px) in renal cortex. Results The extent of RIF and the expression of CTGF,TGF-β1,α-SMA and ColⅢin renal cortex were significantly lower in sodium selenite group and benazepril group at day 7,14 and 21 after the op-eration compared with that in UUO group(P<0.05 or P<0.01). In sodium selenite group and benazepril group,the contents of SOD and GSH-px in renal cortex were higher significantly than those in UUO group at day 7,14 and 21 after the operation respectively(P<0.05),but the MDA in renal cortex was significantly decreased(P<0.05).There were no significant differences in the indexes between the two groups of sodium selenite and benazepril. The expres-sion of CTGF,TGF-β1,α-SMA,ColⅢand the extent of RIF were positively correlated to the level of MDA in UUO group(P<0.05,respectively),and negatively correlated to the level of SOD and GSH-Px(P<0.05,respectively). The expression of CTGF was positively correlated to the expression of α-SMA and ColⅢin UUO group(P<0.05).The expres-sion of CTGF,α-SMA and ColⅢwere positively correlated to RIF in UUO group(P<0.05).Conclusions Sodium sele-nite and benazepril can reduce the extent of RIF in rat model with unilateral ureteral obstruction.

The clinical efficacy of treatment of diabetic nephropathy with Shuxuening injection combined with benazepril / 中国生化药物杂志

Objective To observe the clinical efficacy of treatment of diabetic nephropathy with Shuxuening injection combined with benazepril.Methods 60 cases from January 2014 to January 2015,were randomly divided into observation group and control group of 30 patients.the control group were given benazepril treatment,observation group were based on Shuxuening injection treatment,patients were followed up and record changes related indicators.Results The urinary β2-MG and hs-CRP were after treatment(0.38±0.08,6.29±1.40)mg/L,than the control group(0.48±0.10,7.74±1.36)mg/L,and the difference was significant sex(P<0.05); after treatment observation group 24H urine protein quantitative detection of(0.69±0.50)g/24h,than the control group(1.04±0.63)g/24h,and the difference was statistically significant(P<0.05); After the observation group patients,low-density lipoprotein,serum creatinine value were(359.2±50.3mg/L,2.40±0.63mmol/L,95.6±22.3mol/L),were better than the control group(379.8±48.3mg/L,3.44±0.76mmol/L,108.5±34.2mol/L),and the difference was statistically significant(P<0.05); observation group total effective rate was 90.0％,higher than 73.0 percent,and the difference was statistically significant(P<0.05).Conclusion Shuxuening injection combined with benazepril clinical treatment of diabetic nephropathy exact,no significant side effects,is worthy of further research and application.

Effect of metoprolol combined with benazepril on cardiac structure and function in elderly heart failure / 中国生化药物杂志

Objective To study the effect of metoprolol combined with benazepril on cardiac structure and heart function in patients with heart failure and the treatment of hypertension in the elderly. Methods 120 cases of elderly hypertensive patients with heart failure from June 2011 to June 2015 were studied, according to the random number table method, they were randomly divided into combination group and control group.The two groups were given symptomatic and supportive therapy, the control group on the basis of conventional treatment were given antihypertensive drugs of benazepril; combination treatment group were given metoprolol on the basis of control group. After treatment, the clinical efficacy of the two groups were evaluated, the changes of cardiac structure in the two groups were recorded and analyzed before and after treatment, and the blood pressure and cardiac function were analyzed. Results The total effective rate of the combined group was 91.67%, the control group was 78.33%, there was significant difference between the two groups (χ2=4.1830, P=0.0408). After 6 months of treatment, the blood pressure, cardiac structure and 6min walking distance were significantly improved in the two groups (P<0.05). The above indicators in combination group were significantly better than those in the control group (P<0.05). The complication rate in combination group was 8.33%, 13.33% in the control group, there was no statistically significant between two groups (χ2=0.7764, P=0.3782). Conclusion Metoprolol combined with antihypertensive treatment can significantly improve the clinical efficacy of the treatment, improve the cardiac structure and function.

Curative efficacy of benazepril combined with atorvastatin on plasma NT-proBNP and its efficacy in chronic cardiac failure / 中国生化药物杂志

Objective To study curative efficacy of benazepril combined with atorvastatin on N-terminal pro-brain natriuretic peptide (NT-proBNP) and its efficacy in the treatment of chronic cardiac failure. Methods 90 patients of chronic heart failure were selected as research objects. The control group were treated with benazepril, while the observation group were treated with benazepril combined with atorvastatin, 45 cases in each group. Then before and after treatment of 6 months, the cardiac function of left ventricular end-diastolic dimension (LVEDD), left ventricular end systolic dimension (LVESD), left ventricular eject fraction (LVEF), C-reactionprotein (CRP), interleukin- 6 (IL-6, tumor necrosis factor α (TNF-α) and plasma NT-proBNP levels were compared between two groups, and the efficacy was observed. Results After treatment, LVEDD and LVESD in observation group were lower than those in control group, the LVEF was higher than that in control group(P<0.05). The CRP,IL-6 and TNF-αlevels in observation group were lower than those in control group(P<0.05). The plasma NT-proBNP level in observation group was significantly lower than that in control group(P<0.05). The total effective rate of observation group was statistically higher than that that in the control group 95.55%(43/45)vs. 77.77%(35/45)(P<0.05). Conclusion Benazepril combined with atorvastatin in the treatment of chronic heart failure is significant, can reduce plasma NT-proBNP levels, improve the inflammatory factor.

Effect of benazepril combined with atorvastatin in treatment of chronic heart failure and its effects on level of plasma NT-proBNP / 中国生化药物杂志

Objective To study curative efficacy of benazepril combined with atorvastatin in treatment of chronic heart failure and its effects on level of plasma N-terminal pro brain natriuretic peptide(NT-proBNP). Methods 90 patients of chronic heart failure who received therapy from January 2013 to January 2016 in the first people's Hospital of Xiangshan, Zhejiang. According to random number table, those patients were divided into the observation group and the control group with 45 cases in each group, on the basis of routine treatment, the control group was treated with benazepril, while the observation group was treated with atorvastatin on the basis of control group. After 2 months, the treatment effect was compared. Results After treatment, the left ventricular end diastolic diameter (LVIDd), left ventricular end systolic diameter (LVIDs) in the observation group were lower than the control group, left ventricular ejection fraction (LVEF) was higher than the control group, the difference was statistically significant (P<0.05), the level of NT-proBNP in the observation group was lower than the control group, the difference was statistically significant (P<0.05), 6 minute walking distance was better than the control group, the difference was statistically significant (P<0.05), the total effective rate in the observation group 91.11%(11/45) was higher than the control group 71.11%(32/45), the difference was statistically significant (P<0.05), during the follow-up of 6 months, the recurrence rate of heart failure in observation group 2.22%(1/45) was lower than the control group 20.00%(9/45), the difference was statistically significant (P<0.05). Conclusion Benazepril combined with atorvastatin is well for chronic heart failure, which can effectively reduce the level of plasma NT-proBNP and prognosis.

Clinical Observation of Sitagliptin Combined with Benazepril in the Treatment of Diabetic Nephropathy / 中国药房

OBJECTIVE:To observe the clinical efficacy of sitagliptin combined with benazepril in the treatment of diabetic nephropathy(DN). METHODS:Sixty DN patients admitted to our hospital during Sept. 2014-Jun. 2015 were divided into sitagliptin group,benazepril group,drug combination group according to random number table,with 20 cases in each group. Based on routine treatment,sitagliptin group was given sitagliptin 100 mg orally,qd;benazepril group was given Benazepril 10 mg orally,qd;drug combination group was given sitagliptin 100 mg+benazepril 10 mg orally,qd. The drug dosage would be doubled if the blood pressure of patients in 3 groups had not yet reached the standard. Treatment course of 3 groups lasted for 12 weeks. The levels of 24 h urine protein,IL-6 and Cys-C were measured in 3 groups before and after treatment. Clinical efficacies and the occurrence of ADR were observed. RESULTS:Total response rate of drug combination group(90.00%)was significantly higher than those of sitagliptin group (65.00%)and benazepril group(70.00%);there was statistically significance(P0.05). No obvious ADR was found in 3 groups during treatment. CONCLUSIONS:Both sitagliptin and benazepril can decrease the levels of 24 h urine protein,IL-6 and Cys-C,while drug combination shows better effect and clinical response rate,and does not influence the safety of drug use.

Clinical study of psychological intervention combined with valsartan and Benner Pury in the treatment of congestive heart failure / 中国生化药物杂志

Objective To investigate the clinical efficacy of psychological intervention combined with valsartan and Benner Pury in the treatment of congestive heart failure (CHF). Methods 100 patients with congestive heart failure treated in our hospital from January 2015 to October 2016 were selected and randomly divided into the control group and the experimental group, with 50 patients in each group. Patients in the control group were treated with Benner Pury, the experimental group was given valsartan and Benner Pury combined treatment, and psychological intervention, pay attention to the psychological state of patients. The clinical indexes of the experimental group and the control group were compared and analyzed. Results After the corresponding treatment, the effective rate of treatment in the experimental group was 96%, and the effective rate of the control group was 82%. The effective rate of the patients in the control group was significantly lower than that in the experimental group, with statistical difference (P<0.05). The incidence of adverse reactions in the experimental group was 8%, and the fatality rate was 10%. The incidence of adverse reactions in the control group was 10%, and the fatality rate was 12%. There was no significant difference between the experimental group and the control group in the incidence of adverse reactions and mortality, and it was not statistically significant, and could be compared. Conclusion The clinical effect of psychological intervention combined with valsartan in the treatment of congestive heart failure, Benner Pury good, can improve the treatment efficiency to a certain extent, high safety, is further applied in clinical significance.

Clinical study of valsartan combined with benazepril in the treatment of congestive heart failure / 中国生化药物杂志

Objective To analyze the therapeutic values of valsartan combined with benazepril in the treatment of patients with congestive heart failure.Methods 102 cases of patients with congestive heart failure in Nine 0 Third Hospital were enrolled in the study.They were randomly divided into the control group and the observation group, with 51 cases in each group.Both groups were given cardiac diuretic, anti-infection and other basic treatment and the control group was given benazepril on the basis of basic treatment while the observation group was additionally given valsartan on the basis of treatment in the control group.The curative effects were compared and the changes of cardiac function indexes were detected before and after treatment between the two groups.Results The effective rate of treatment was 80.39% in the control group, which was lower than that in the observation group with 96.08% (P<0.05).After treatment, the observation group LVEF increased significantly, LVESd and LVEDd decreased significantly, and each index was significantly better than that of the control group (P<0.05).Conclusion Valsartan combined with benazepril in the treatment of congestive heart failure can effectively relieve the clinical symptoms and improve the cardiac function, therefore it is worthy of clinical promotion.